Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SmofKabiven Extra Nitrogen in ICU Patients
NCT05257031Phase 3Completed
- Sponsor
- Fresenius Kabi
- Start
- Feb 2022
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of SmofKabiven extra Nitrogen in critical illness, sponsored by Fresenius Kabi. Primary endpoint: Protein intake during the study treatment period. Started Feb 2022; status: completed.
02
Drugs
SmofKabiven extra Nitrogen
03
Conditions
critical illness
Beyond the preview
Go deeper on NCT05257031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05257031.